Table 4.

Comparative user experience data following abatacept autoinjector use in (A) the formative study or (B) the summative study, from participants who had previously administered injections with an alternative autoinjector

Rating	Patients (n = 12)			Caregivers (n = 5)			Healthcare professionals (n = 10)
	Mean abatacept autoinjector rating	Mean competitor autoinjector rating	Mean paired difference	Mean abatacept autoinjector rating	Mean competitor autoinjector rating	Mean paired difference	Mean abatacept autoinjector rating	Mean competitor autoinjector rating	Mean paired difference
(A) Formative study
Comfort	6.6	4.6	P = 0.0033	7.0	4.2	P = 0.0135	6.8	4.5	P < 0.0001
Control	6.8	4.6	P = 0.0025	7.0	4.0	P = 0.0132	6.7	4.6	P = 0.0095
Ease of use	7.0	5.9	P = 0.0006	7.0	5.2	P = 0.0533	6.8	5.2	P = 0.0046
Confidence of dose	6.8	6.3	P = 0.0819	7.0	5.8	P = 0.2080	6.4	5.6	P = 0.2999
Overall acceptability	6.7	5.2	P = 0.0001	7.0	4.6	P = 0.0093	6.8	5.1	P = 0.0020

Rating	Patients (n = 25)			Caregivers (n = 12)			Healthcare professionals (n = 13)
	Mean abatacept autoinjector rating	Mean competitor autoinjector rating	Mean paired difference	Mean abatacept autoinjector rating	Mean competitor autoinjector rating	Mean paired difference	Mean abatacept autoinjector rating	Mean competitor autoinjector rating	Mean paired difference
(B) Summative study
Comfort	6.4	5.2	P = 0.0157	6.4	5.4	P = 0.0671	6.8	5.2	P = 0.0017
Control	6.9	5.6	P = 0.0002	6.9	5.8	P = 0.0081	6.8	4.5	P = 0.0001
Ease of use	6.5	5.8	P = 0.0210	6.8	5.8	P = 0.0039	6.6	5.0	P = 0.0012
Confidence of dose	6.4	6.4	P = 0.8960	6.8	6.3	P = 0.2098	6.7	5.2	P = 0.0112
Overall acceptability	6.5	5.9	P = 0.0404	6.8	5.8	P = 0.0047	6.8	5.1	P = 0.0002

Each score was quantified using a 7-point scale, where 1 = very unacceptable, 4 = neutral, and 7 = very acceptable

Analyses were restricted to those participants who provided both abatacept and competitor autoinjector ratings